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Abstract.  The active form of fibronectin is its ex- 
tracellular matrix form, which allows  for the attach- 
ment of cells and influences both the growth and mi- 
gration of cells. The matrix form is assembled by 
cells; however,  many cells are defective in this regard. 
Several  regions within fibronectin have been shown to 
play a role in matrix assembly by cells.  One such re- 
gion has been localized into the first type III repeat of 
fibronectin (Chernousov, M. A., E  J.  Fogerty,  V.  E. 
Koteliansky, and D.  E  Mosher. J.  Biol.  Chem. 
266:10851-10858).  We have identified this site as a 
fibronectin-fibronectin binding site and reproduced it 
as a synthetic peptide.  This site is contained in a  14- 
kD fragment that corresponds to portions of the first 
two type HI repeats.  The  14-kD fragment was found 
to bind to cell monolayers and to inhibit fibronectin 
matrix assembly. The  14-kD fragment only slightly re- 
duced the binding of fibronectin to cell surfaces but it 
significantly inhibited the subsequent incorporation of 
fibronectin into the extracellular matrix. The  14-kD 
fragment also bound to purified fibronectin and inhib- 
ited fibronectin-fibronectin binding. A synthetic 
31-amino  acid peptide (P1) representing a segment of 
the  14-kD fragment retained the ability to inhibit 
fibronectin-fibronectin binding. Peptide P1  specifically 
bound fibronectin from plasma in affinity chromatog- 
raphy,  whereas a column containing another peptide 
from the 14-kD fragment did not. These results define 
a fibronectin-fibronectin binding site that appears to 
promote matrix assembly by allowing the assembly of 
fibronectin molecules into nascent fibrils.  The  14-kD 
fragment and the P1  peptide that contain this site in- 
hibit matrix assembly by competing for the fibronectin- 
fibronectin binding. 
a constituent of the extracellular  matrix,  fibronectin 
is important for allowing cells to attach to the ma- 
trix and influences both the growth and migration of 
cells (McDonald,  1988; Ruoslahti,  1988; Ruoslahti and Gi- 
ancotti,  1989; Hynes,  1990; Mosher et al.,  1991). Normal 
fibroblasts in tissue culture secrete fibronectin and assemble 
it into a matrix that is essential to their adhesion and growth. 
While many tumorigenic cells continue to produce fibronec- 
tin, they do not assemble the fibronectin into a matrix,  and 
this lack of matrix assembly is thought to contribute to the 
invasive properties of malignant cells (Ruoslahti and Gian- 
cotti,  1989; Hynes, 1990). Thus, one important stage in the 
progression of cancer may be the transition from assembly 
to nonassembly of the extracellular  matrix. 
Matrix assembly requires the binding of  fibronectin to cell 
surfaces followed by assembly into fibrils and stabilization 
of the  fibrils  by  disulfide  cross  linking.  Several  regions 
within fibronectin are needed for the assembly process. One 
such region  is the amino-terminal  29-kD heparin-binding 
domain.  Oh et al.  (1981) found that truncated  fibronectin 
molecules that lacked amino- and carboxy-terminal regions 
were not incorporated  into extracellular  matrices  in vivo. 
Further  evidence  for  the  importance  of amino-terminal 
regions of fibronectin in matrix assembly was obtained by 
McKeown-Longo and Mosher (1985) who demonstrated that 
an  amino-terminal  70-kD  fragment  of fibronectin,  when 
added to fibroblast culture medium, inhibited the binding of 
exogenous fibronectin to cells and its subsequent incorpora- 
tion into the matrix.  They found that the active area within 
the 70-kD fragment was the amino-terminal 29-kD heparin- 
binding domain, whereas the 40-kD gelatin-binding domain 
did not inhibit matrix assembly. The sites on cells to which 
the 70-kD fragment binds have been localized to the edges 
of cells (Peters and Mosher, 1987), suggesting the existence 
of distinct matrix assembly sites. Also, two candidate cell 
surface receptors for the 70-kD fragment have been detected 
(Limper et al., 1991; Blystone and Kaplan,  1992). The 70- 
and 29-kD fragments have also been shown to inhibit matrix 
assembly of  endogenous fibronectin (McDonald et al., 1987). 
In addition,  cells have been shown to organize fibronectin 
fragments into fibrils only when an RGD-containing  cell- 
binding domain and heparin-binding fragments were coated 
onto dishes simultaneously  (Woods et al.,  1988). The im- 
portance of the 29-kD heparin-binding domain was further 
underscored by the finding that recombinant fibronectin mol- 
ecules that lacked the 29-kD region were not incorporated 
into the matrix (Schwarzbauer, 1991). Moreover, molecules 
composed only of the 29-kD region plus the carboxy-termi- 
nal half of the protein were efficiently incorporated into the 
extracellular matrix (Schwarzbauer, 1991). The role of the 
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nectin to the cell surface (McKeown-Longo and Mosher, 
1985;  Quade and McDonald,  1988). 
Another region involved in matrix assembly is the RGD- 
containing cell-binding  domain of fibronectin,  mAbs  di- 
rected to the cell-binding domain of fibronectin were found 
to inhibit matrix assembly (McDonald et al.,  1987).  Two 
mAbs have been described that bind close to, but not directly 
to, the RGD site and block the binding of cells to fibronectin 
(Nagai et al., 1991). These antibodies also blocked fibronec- 
tin matrix assembly. The receptor that binds to the RGD site 
in fibronectin is, in most cells, the txsflt integrin (Piersch- 
bacher and Ruoslahti, 1984;  Pytela et al.,  1985).  Accord- 
ingly, mAbs directed against the c~5 and fl~ integrin subunits 
were also found to inhibit fibronectin matrix assembly and 
the binding of  fibronectin to matrix assembly sites (Akiyama 
et al., 1991; Fogerty et al., 1990).  In addition, overexpres- 
sion of txsfll in CHO cells resulted in increased fibronectin 
matrix assembly  (Giancotti and Ruoslahti,  1990).  These 
findings establish the importance of the interaction between 
fibronectin and the ctsfll integrin during matrix assembly. 
A third region in fibronectin has recently been shown to 
be involved in matrix assembly. A  56-kD  fragment from 
fibronectin, containing the 40-kD gelatin-binding domain, 
plus the first type llI repeat, inhibits the incorporation of ex- 
ogenous fibronectin into the matrix and mAbs localize the 
active site into the first type III repeat of fibronectin (Cher- 
nousov et al.,  1991). 
In this report we describe a 14-kD fragment from the first 
two type III repeats of fibronectin. We provide evidence that 
the region defined by this fragment represents a fibronectin- 
fibronectin binding site, and show that the 14-kD  fragment 
inhibits fibronectin matrix assembly. In addition, we show 
that a synthetic peptide derived from the 14-kD region also 
binds directly to fibronectin and inhibits fibronectin-fibro- 
nectin association. In contrast to the 29- and 70-kD frag- 
ments, which block an initial event in matrix assembly (fibro- 
nectin binding to cells), the 14-kD fragment may inhibit an 
intermediate step in matrix assembly, fibronectin self-asso- 
ciation, before the disulfide cross linking that stabilizes the 
fibronectin matrix. 
Materials and Methods 
Materials 
Alpha~minimal  essential  medium (a-MEM) was purchased from Gibco 
Laboratories (Grand Island, NY),  FCS from Tissue Culture Biolngicals 
(Tnlare, CA), and Glutamine Pen-Strop from Irvine Scientific (Santa Aria, 
CA). Immulon 2 Removawell strips were obtained from Dynatech Labora- 
tories (ChantiUy,  VA). Iodo-Gen was  purchased from Pierce Chemical 
Co.  (Rockford,  IL).  CNBr-activnted  Sepharose,  heparin-Sepharose,  and 
gelatin-Sepharose  were obtained from Pharmacia LKB (Piscataway, NJ). 
Precast SDS-PAGE gels were purchased from BioRad Laboratories (Rich- 
mond, CA) and Novex (San Diego,  CA).  Lab-Tek 8-weU Chamber Slides 
were obtained from Hunt (Naperville,  IL). HPLC columns were purchased 
from Vydac (Hesperia,  CA). Collagen type I was obtained from Collabora- 
tive Research (Bedford, MA). All other reagents were acquired from Sigma 
Chemical Co.  (St.  Louis,  MO). 
Cell Culture 
IMR-90 and HT-1080 cells were cultured in c~-MEM supplemented with 
10 % heat-inactivated  FCS and Glntamine Pen-Strep. IMR-90 cells used for 
experiments  were between passages  number 11 and 20; cells in later pas- 
sages were not used. 
F[bronectin Fragments 
Human fibronectin was obtained from the Blood Transfusion Service of the 
Finnish Red Cross in Helsinki. To prepare the heparin-binding fragments, 
fibronectin in PBS  was digested  with ~-chymotrypsin (0.1% by weight, 
TLCK treated) for 4 h at 25~  The digestion was stopped by adding PMSF 
(20 ~g/rnl  final  concentration) and the preparation was  passed over a 
gelatin-Sepharose  column (Engvall and Ruoslahti,  1977). After washing the 
gelatin-Sepharose  column with PBS,  gelatin-bound material was  eluted 
with 8 M urea,  50 raM Tris-HCl, pH 7.5, followed by extensive dialysis 
against distilled water and lyophilization. The flow-through from the gelatin- 
Sepharose  column  was  collected and passed  over a  heparin-Sepharose 
column preequilibrated with PBS.  The  heparin-Sepharose column was 
washed  with PBS, then heparin-bouod fibronectin fragments were eluted 
with 1 M NaC1, 50 mM Tris-HCl, pH 7.5, then dialyzed  against distilled 
water and lyophilized. 
The amino-terminal 70-kD fragment was produced as previously  de- 
scribed by McKeown-Longo  and Mosher (1985). The 14-kD fragment was 
purified from heparin-binding fragments by reverse  phase HPLC using 
a  C-4 column.  After applying  beparin-hinding fragments  to the HPLC 
column in 0.06% trifluoroacetic  acid, the column was elnted with a linear 
gradient of 0-60% acetonitrile in 0.06% trifluoroacetic  acid.  The 14-kD 
fragment was eluted in the 45% acetonitrile fractions. 
Peptides representing various regions of fibronectin were synthesized at 
the Protein Chemistry Laboratory at the La Jolla Cancer Research Founda- 
tion (La Jolla, CA). All peptides used in experiments were purified by re- 
verse phase HPLC.  Peptide Pl  represents the region from amino acids 
600--630 (sequence; NAPQPSHISKYILRWRPKNSVGRWKEATIPG);  pep- 
tide  P2  from 625-656  (sequence; EATIPGHLNSYTIKGLKPGVVYE- 
GQLISIQQ);  peptide  P3  from 650-680  (sequence;  LISIQQYGHQEV- 
TRFDFTTTSTSTPVTSNTV);  and peptide P4 from 675-708 (sequence; 
VTSNTVTGETTPFSPLV ATSESVTEITASSFVVS) of the mature protein 
according to the numbering method of Kornblihtt et al. (1985). 
I  odination of  Proteins 
Proteins (20-100/~g of protein in 0.1 ml 50 ram KPO4, pH 7.5) were iodi- 
hated by using Iodo-Gen as previously described (Fraker and Speck,  1978). 
Typical  values  for specific  activity  were  109 ;tCi/mmol for fibronectin, 
5  ￿  l0  s /~Ci/mmol for 70 kD,  5  ￿  108/~Ci/mmol  for  14 kD,  and 0.5 
/tCi/~g for heparin-binding fragments. 
Matrix Assembly Assays 
Matrix assembly assays were performed by using 125I-fibronectin, essen- 
tially as described previously  (McKeown-Longo  and Mosher, 1983, 1985). 
Before  the assay, cells were  grown to confluence in 96-well  dishes in 
c~-MEM +  10% FCS. Cells were incubated in c~-MEM +  10% fibronectin- 
deficient FCS plus 5/~Ci/ml of 1251-fibronectin. Fibronectin-deficient  FCS 
was prepared by passing FCS over a gelatin-Sepharose  column to remove 
fibmnectin (Engvall and Ruoslahti,  1977). The concentration of unlabeled 
fibronectin in ~-MEM +  10% fibronectin-deficient  FCS was ,-00.2 ~g/rnl 
as determined by ELISA using antibovine fibronectin antibodies.  Where in- 
dicated, cells were incubated in the presence of excess nonradioactive com- 
petitor proteins such as fibronectin, the 70-kD fragment, or the 14-kD frag- 
ment. Ceils that were labeled for 1 h were washed four times with ice-cold 
PBS, then lysed in 1 N NaOH, and cell-bound radioactivity  was measured 
in the NaOH soluble fraction. Cells that were incubated with t25I-heparin- 
binding fragments were also washed with PBS, then cells were solnhilized 
with SDS-PAGE sample buffer (2% SDS, 67 raM Tris-HC1, pH 6.8, 10% 
glycerol, 0.03 % bromophenol blue), and proteins were separated on BioRad 
4-20% Ready Gels, followed by autoradiography.  Cells that were incubated 
with 1251-fibronectin  for 24 h were washed as described above and proteins 
were separated into 1% deoxycholate  soluble and insoluble pools (pools I 
and II) as described by McKeown-Longo and Mosher (1985). Specific bind- 
ing was defined as that amount of binding which was competed by 2/~M 
unlabeled fibronectin,  and was typically 60-70% of the total 125I-fibronec- 
tin binding. Cells that were labeled with t251-70 kD or t2Sl-14 kD also re- 
ceived  5  #Ci/ral  of  labeled protein.  As  with  t25I-fibronectin  labeling, 
specific binding was defined by inhibiting the binding of the radiolabel with 
unlabeled ligand. 
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Protein-protein binding assays were performed on Immulon 2 Removawell 
strips. Pr~ins were coated onto wells in 100 mM NazCO3, pH 9.5, in a 
moist chamber at 4"C overnight. The wells were washed three times with 
PBS followed  by blocking with 0.2% BSA in PBS (0,2% BSA) at 37"C for 
1 h.  100/~1 of 5 ttCi/ml radiolabeled protein solution in 0.2% BSA was 
added to each well. Proteins were allowed to bind for 2 h at 37~  then the 
wells were washed four times with 0.2% BSA, the wells were removed, and 
the bound nsI was measured. 
Affinity Chromatography with Peptide Columns 
Peptides were coupled to CNBr-activated Sepharnse CL-4B according to 
the manufacturer's recommendations. The concentration of peptide was 
typically 8-10 nag peptide/ml of resin. In affinity chromatography, lO-ral 
aliqnots of a 250-t~g/ml solution of purified human plasma fibronectin in 
PBS were applied to freshly made, l-ml columns of peptide Pl, or peptide 
P2-Sephamse, or gelatin-Sepharose  as a positive control. The flow-through 
fractions were collected and each column was then washed with 20 ml of 
PBS. The wash fractions were collected, and the fibronectin bound to each 
column was einted with 5 ml of 8 M urea in PBS. The amount of  fibronectin 
in the samples was quantitated by measuring the A2so. 
Alternatively, l-ml columns of peptide  P1,  peptide  P2,  or gelatin- 
Sepharose received 5-ml aliquc~s of human plasma which were diluted 
fivefold  with PBS + 5 mM EDTA  (PBS/EDI'A).  The flow-through  fractions 
were collected and the columns were washed with 20 ml of PBS/EDTA. 
Bound proteins were then eluted with step gradients of urea by using 0.5, 
1, 2, 3, 4, 5, 6, 7, and 8 M urea in PBS/EDTA. At each step, 2 ml of urea 
solution were passed over the columns and the eluates were collected. Equal 
volumes of  each fraction were analyzed  by SDS-PAGE  under reducing con- 
ditions on Novex  4-20% Tris-Glycine  gels, and proteins were visualized by 
staining with Coomassie blue. 
Fluorescence  Assays  for Fibronectin Fibril Formation 
IMR-90 cells were seeded onto Lab-l"~k  8-well  Chamber Slides, Wells were 
prec~ted with 50 t~gtml  collagen type I to enhance the attachment of  cells 
to the wells. We found that cells not seeded onto collagen-coated wells 
tended to detach when treated with high concentrations of the 70-kD frag- 
ment for prolonged  periods of  time. Cells were allowed  to attach and spread 
for 1 h at 370C, followed  by washing  once with cr-MEM +  10% fibronectin- 
deficient FCS, and incubation in this medium plus either no additions or 
addition of the 70-kD fibronectin fragment or the 14-kD fragment as de- 
scribed in the legend to Fig. 9. 24 h before fixation for microscopy,  fluores- 
cein-labeled fibronectin (prepared as described by McKeown-Longo  and 
Mosher, 1985) was added to the cultures to a final concentration of 10 
~,g/ml. At the appropriate time, cells were fixed with 3.7 % paraformalde- 
hyde, 60 mM sucrose, in PBS, pH 7.4, for 30 rain at room temperature. 
Cell layers were then washed three times with 0.2% BSA in PBS and 
mounted for microscopy. 
Figure L Binding of 29- and 
14-kD  fragments to IMR-90 
cells. IMR-90 cells were incu- 
bated for  1  h  at  37~  with 
nSI-labeled  heparin-binding 
fragments  (2  /~Ci/ml)  in  the 
presence or absence of unla- 
beled  heparin-binding  frag- 
ments (250 ~g/ml), or 70-kD 
0 ~M). Cells were then washed 
with  PBS  and  harvested for 
analysis by SDS-PAGE as de- 
scribed  in  Materials  and Meth- 
ods.  (Lane A)  A  sample of 
the nSI-labeled heparin-bind- 
ing fragment starting material; (lane B) fragments that bound in the 
absence of competition; (lane C) fragments bound in the presence 
of unlabeled heparin-bindiag fragments; (lane D) fragments bound 
in the presence of unlabeled 70-kD.  The positions of molecular 
mass standards are indicated to the left of the gel. 
fragment preparation were responsible for inhibiting matrix 
assembly,  l:5I-labeled heparin-binding fragments  were  in- 
cubated with IMR-90 cell monolayers. Only two of the many 
heparin-binding fragments,  a  29-  and  a  14-kD  fragment, 
Results 
Inhibition of  Matrix Assembly by a 14-kD 
Heparin-binding Fibronectin Fragment 
To identify new fibronectin fragments that would define sites 
important  for  matrix  assembly,  fibronectin  was  digested 
with chymotrypsin and the preparation was separated into 
heparin-binding and gelatin-binding fragments. The fragment 
preparations were then tested for their ability  to inhibit fibro- 
nectin matrix assembly by using  nsI-fibronectin and IMR- 
90 cells. As shown previously, unlabeled fibronectin and an 
amino-terminal 70-kD cathepsin-D fibronectin fragment in- 
hibited matrix assembly in this assay (McKeown-Longo and 
Mosher, 1985). Among the r  fragments, the hep- 
arin-binding fragments inhibited matrix assembly, whereas 
the gelatin-binding fragments had tittle effect (not shown). 
To  determine  which  fragments  in  the  heparin-binding 
Figure 2. Purification of the 14-kD fibronectin fragment and its lo- 
cation in fibronectin. The  14-kD heparin-binding fragment was 
purified to homogeneity by reverse phase HPLC. A shows SDS- 
PAGE analysis of the heparin-binding fragment starting material 
(lane a), and the purified 14-kD preparation (lane b). The gel was 
stained with Coomassie blue.  The positions of molecular mass 
standards are indicated to the left of the gel. The position of the 
14-kD fragment is indicated to the right of the gel. B shows a dia- 
gram of fibronectin, outlining the locations of the 14-kD fragment 
and the various other fragments relevant to this work. The three re- 
peating units of fibronectin are depicted as follows: type I repeats 
(circles);  type  H repeats (d/amonds); type  IlI  repeats (squares).  The 
CS1 region is depicted by a shaded oval. The amino-terminal se- 
quence of the 14-kD fragment is shown with dashed lines extending 
to the location on the diagram representing the area covered by the 
14-kD fragment. 
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Figure 3.  Inhibition  of fibro- 
nectin  binding  to  cells  and 
matrix  assembly  by  the  14- 
kD  fragment.  (A)  Confluent 
monolayers  of IMR-90  cells 
were incubated with ~25I-fibm- 
nectin in the presence of vari- 
ous  concentrations  of  unla- 
beled  fibronectin  (.),  70-kD 
fragment (e), or 14-kD frag- 
ment (A) for either  1 or 24 h, 
as indicated.  Cells that  were 
incubated for 1 h were washed 
and  the  total  radioactivity 
bound  was  measured.  Cells 
that  were incubated  for 24 h 
were washed and the amount 
of '25I-fibronectin in  the  de- 
oxycholate insoluble pool was 
measured.  Each data point is 
the average of duplicate deter- 
minations. (B) Semiconfluent 
IMR-90 cells layers were in- 
cubated  for  1 h  with  either 
t25I-fibronectin (left),  1251-70- 
kD fragment (center),  or t25I- 
14-kD fragment (right)  in the 
presence  or absence  of unla- 
beled  fibronectin  (FN),  70- 
kD fragment (7Ok), or 14-kD 
fragment  (14k) as  indicated. 
After the  1-h labeling period 
cells were washed and the to- 
tal  radioactivity  bound  was 
measured. 
bound to the IMR-90 cells (Fig.  1, lane B). The binding of 
both fragments was shown to be specific by competition with 
excess unlabeled heparin-binding fragments (Fig.  1, lanes B 
and C).  Unlabeled 70-kD fragment competed for the bind- 
ing of the 29-kD heparin-binding  fragment, indicating that 
this fragment represents the amino-terminal heparin-binding 
domain (Fig.  1, lane D). Interestingly, the 70-kD fragment 
did  not  compete for the  14-kD heparin-binding  fragment 
(Fig.  1, lane D), suggesting that the 14-kD region is not rep- 
resented in the 70-kD fragment. 
To  characterize  the  14-kD  fragment it  was  purified  to 
homogeneity by using reverse phase HPLC (Fig.  2 A, lane 
b).  Amino  acid  sequencing  yielded  the  following  amino- 
terminal  sequence:  NAPQPSHISKYILRW. This  sequence 
corresponds to a region just past the beginning of the first 
fibronectin type III repeat (see Fig. 2 B), starting at amino 
acid  residue  600  of the  mature protein  (according  to the 
numbering of Kornblihtt et al., 1985). Judging from the size 
of the fragment, it is likely to encompass a sequence that ex- 
tends partially into the second type III repeat. 
Because fibronectin does not bind to monolayers of cells 
that do not deposit a fibronectin matrix, we next determined 
the binding of the 14-kD fragment to HT-1080 cells, which 
produce no matrix. While "o50-60% of the ~251-14-kD frag- 
ment bound specifically to IMR-90 ceils, which construct an 
extensive fibronectin matrix, no specific binding to HT-1080 
cells was detected (not shown). 
Both fibronectin and the 70-kD fragment completely in- 
hibited the binding of t25I-fibronectin  to IMR-90 ceils in a 
1-h binding assay, but the 14-kD fragment was only partially 
inhibitory (Fig. 3 A, left). The 14-kD fragment had a much 
more pronounced effect on the amount of fibronectin incor- 
porated into the extracellular matrix after 24 h of incubation 
of ceils with ~25I-fibronectin. As shown in Fig.  3 A  (right), 
the 14-kD fragment inhibited the fibronectin matrix assem- 
bly defined by this assay by ,o70% (at 5/~M, the highest con- 
centration tested).  The ICs0 of the  14-kD fragment was be- 
tween 1 and 2 #M, which was 5-10-fold higher than that of 
fibronectin or the 70-kD fragment. Thus, the purified 14-kD 
fragment inhibits fibronectin matrix assembly. 
The 14-kD fragment did not significantly reduce I251-70- 
kD binding to cells,  although,  as expected, this was com- 
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Figure 5.  Binding  of the  14- 
kD  fragment  to  fibronectin. 
Plastic wells were coated with 
various concentrations of fibm- 
nectin,  blocked  with  BSA, 
then  probed  with  t251-14-kD 
(A),  or  ~25I-fibronectin (B) 
for 2 h at 37~  The amount of 
radioiodinated  protein  bound 
was  measured  after washing 
extensively with 0.2 % BSA in 
PBS.  Each  data point  is the 
average of duplicate  determi- 
nations. 
Figure 4.  Inhibition  of fibronectin  fibril formation by the  14-kD 
fragment. IMR-90 cells were seeded onto slides that had been pre- 
coated with collagen type I. After attaching for 1 h at 37~  cells 
were cultured for 5 d in 10% fibronectin-deficient medium plus ei- 
ther no additions (A and B), or 200/~g/ml 70-kD fragment (C and 
D), or 100 #g/ml 14-kD fragment (E and F). On day 5 cells were 
given  10/~g/ml of fluorescein-labeled  fibronectin for 24 h.  Cells 
were then fixed with paraformaldehyde  and the fluorescent fibro- 
nectin  in the matrix  was visualized by fluorescence  microscopy. 
The panels show representative fields from each culture. A, C, and 
E are fluorescent images, and B, D, and F are the corresponding 
phase-contrast  images. Bar, 25/~m. 
pletely inhibited by fibronectin and the 70-kD fragment (Fig. 
3 B,  center).  In the  reciprocal experiment,  the binding  of 
~251-14-kD fragment to cells was completely blocked by un- 
labeled 14-kD fragment, whereas fibronectin inhibited only 
slightly and the 70-kD fragment was not inhibitory (Fig.  3 
B, right). These data indicate that the  14-kD fragment does 
not compete for the binding of the 70-kD fragment to cells, 
and thus must inhibit matrix assembly by some mechanism 
other than the inhibition of the binding of fibronectin to ma- 
trix assembly sites. 
When matrix assembly was measured by incorporation of 
fluorescent fibronectin into fibrils in the IMR-90 cell layers, 
both the 70- and 14-kD fragments significantly reduced the 
degree of fibril formation, while not significantly affecting 
cell  morphology (Fig.  4).  This provided further evidence 
that the  14-kD fibronectin fragment is able to inhibit fibro- 
nectin matrix assembly. 
The Purified 14-kD Fragment Binds to Fibronectin 
and Inhibits Fibronectin-Fibronectin Association 
To examine the mechanism by which the 14-kD fragment in- 
hibits matrix assembly, the ability of this fragment to interact 
with  fibronectin  was  tested.  As  shown  in  Fig.  5,  ~25I- 
fibronectin and 1~51-14-kD fragment both bound to fibronec- 
tin coated on the plastic in a  dose-dependent manner.  The 
total 12~I-14-kD bound was higher than the total amount of 
~25I-fibronectin bound (compare Fig. 5, A to B). Taking into 
account the specific activities, the levels of binding indicated 
that the maximal binding of the 14-kD fragment to fibronec- 
tin  was  '~10-fold  more  efficient  on  a  molar  basis  than 
fibronectin binding  to  fibronectin.  Typically,  1-2 %  of the 
fibronectin  added  in  solution  bound  to  fibronectin-coated 
dishes,  while  15-20%  of the  14-kD  fragment  bound  to 
fibronectin-coated dishes. 
Unlabeled  14-kD  fragment competed efficiently for the 
binding  of  '251-14-kD fragment  to  fibronectin,  thereby 
demonstrating the specificity of this binding (Fig. 6 A). Yet, 
unlabeled  fibronectin  did  not  compete for  the  binding  of 
~zsI-14-kD fragment to fibronectin. One explanation for this 
is that the unlabeled fibronectin is binding to the fibronectin 
coating,  and  that  ~251-14-kD fragment then binds  to  either 
the coated or the adsorbed fibronectin. 
Besides competing for 14-kD-fibronectin binding, the ex- 
cess unlabeled 14-kD fragment also competed for fibronec- 
tin-fibronectin binding (Fig. 6 B). At the highest concentra- 
tion tested (5/xM), the 14-kD fragment inhibited the binding 
of  fibronectin  to  fibronectin  by  >50%.  As  with  14-kD- 
fibronectin binding,  unlabeled fibronectin did not compete 
for the fibronectin-fibronectin binding, probably due to the 
reasons  mentioned  above.  Thus,  the  14-kD  fragment  of 
fibronectin  that  inhibited  matrix  assembly,  also  binds  to 
fibronectin directly, and inhibits fibronectin-fibronectin as- 
sociation. 
In  similar  assays,  radiolabeled  70-kD  fragment did  not 
bind to fibronectin-coated plastic (not shown). This indicates 
that no sites responsible for fibronectin-fibronectin binding 
are contained within the amino-terminal 70-kD region. 
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Figure 6.  Inhibition of fibro- 
nectin-fibronectin binding by 
the  14-kD fragment.  Plastic 
wells were coated with 5/zg/ 
ml fibronectin, blocked with 
BSA, then probed  with  1251- 
14 kD (A), or t2sI-fibronectin 
(B), in the presence of  various 
concentrations  of  unlabeled 
14 kD (*) or fibronectin (i). 
The solutions were incubated 
for 2 h at 37~  followed by 
extensive washing with 0.2% 
BSA in PBS, and measurement 
of the radioactivity bound to 
the wells. Each data point is 
the average of duplicate deter- 
minations. 
A 31-Amino Acid Peptidefrom the 14-kD Fragment 
Inhibits Fibronectin-Fibronectin  Binding 
Four peptides (of 30-34 amino acids each) were synthesized, 
representing the region of fibronectin encompassed by the 
14-kD fragment (peptides P1-P4). Peptide P1 was the most 
efficient at inhibiting the binding of the 14-kD fragment to 
fibronectin, with an ICs0 of 1 #M; peptides P2 and P3 were 
,,ol00-fold less potent (Fig. 7 A). Peptide P4 did not inhibit 
the 14-kD-fibronectin association, rather, at concentrations 
above 100 #M,  it stimulated this association (not shown), 
The reason for the enhancement of binding by peptide P4 is 
not clear; it is possible that peptide P4 represents part of a 
fibronectin-binding domain. However, since peptide P4 did 
not inhibit the binding of 14-kD to fibronectin, it is not likely 
to be as important in fibronectin self-association as the pep- 
tide P1 region. As shown in Fig. 7, a nonrelated peptide (a 
peptide representing the cytoplasmic domain of the integrin 
o~s subunit) had no effect on 14-kD-fibronectin association. 
Peptide P1 also proved to be the most potent among the 
peptides at inhibiting fibronectin-fibronectin  binding, giving 
an ICso of ,'oi  #M (Fig. 7 B). The only other peptide that 
inhibited  fibronectin-fibronectin binding  was  peptide  P3 
with an ICs0 of 200-300 #M (Fig. 7 B). 
One unexpected result was found.  While peptide P1  in- 
hibited fibronectin-fibronectin  association at low concentra- 
tions  (0.1-50  #M),  at high  concentrations  it actually en- 
hanced the binding of fibronectin to the wells (Fig. 7 B). We 
have found that at high concentrations peptide P1 aggregates 
and can be pelleted by high speed centrifugation, and that 
this does not happen with peptide P2 (not shown). It is possi- 
ble that at high concentrations peptide P1  aggregates into 
multimers and binds to the coated fibronectin and that the 
*2sI-fibronectin probe becomes incorporated into these pep- 
tide P1/fibronectin complexes. This could lead to the ob- 
served increase in signal seen with P1 concentrations above 
100 #M, because as shown below, fibronectin binds directly 
to peptide P1. Thus, the ability of the 14-kD fragment to in- 
hibit fibronectin-fibronectin  binding was also shared by pep- 
tide  P1,  which  was  modeled after the amino-terminal  31 
residues of the 14-kD fragment. 
Peptide P1 Binds to Fibronectin 
To study the binding of fibronectin to peptide P1 or the other 
peptides, the peptides were coupled to Sepharose beads and 
the resins were tested in affinity chromatography for their 
ability to bind purified fibronectin. As shown in Fig.  8 all 
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Figure Z Inhibition of fibro- 
nectin-fibronectin association 
by a peptide from the  14-kD 
region.  Plastic  wells were 
coated with 5 #g/ml fibronec- 
tin,  blocked with BSA, then 
probed  with  1251-14-kD (A), 
or t2sI-fibronectin (B), in the 
presence  of various  concen- 
trations of unlabeled beparin- 
binding  fragments  (m), pep- 
tide PI  (e), peptide P2 (*), 
peptide P3 ([3), or an us cyto- 
plasmic domain peptide as a 
negative control (o). The so- 
lutions were incubated for 2 h 
at 37~  followed  by extensive 
washing with  0.2%  BSA  in 
PBS, and measurement of the 
radioactivity  bound  to  the 
wells. The concentration val- 
ues shown for heparin-bind- 
ing fragments refer to the final 
concentrations of the  14-kD 
fragment in the solutions. 
The Journal of Cell Biology, Volume  118, 1992  426 Figure 8.  Binding of purified  fibronectin to peptide PI in affinity 
chromatography.  1-ml Sepharose columns coupled to either gela- 
tin, peptide P1, or peptide P2 received 10 ml of  a 250-/~g/ml  solution 
of  purified human plasma fibronectin in PBS. The unbound fraction 
from each column was collected and the columns were washed with 
20 ml of PBS, followed by elution with 5 ml of g M urea in PBS. 
The total amount of fibronectin recovered in the unbound fractions 
(cross-hatched  bars),  the  wash  fraction  (shaded  bars),  and  the 
eluted fractions (solid bars) was quantitated by measuring the ab- 
sorbance  of each solution at 280 nm. 
of the fibronectin in the solution bound to either the gelatin- 
Sepharose or P1-Sepharose columns. None of the fibronectin 
bound to the P2-Sepharose column. The binding capacity of 
the P1-Sepharose column was comparable to that of gelatin- 
Sepharose; both columns were able to bind at least 2.5 mg 
of fibronectin per ml of resin. 
We next tested the ability of the P1 and P2 columns to bind 
fibronectin selectively from a  complex mixture of proteins 
by using human plasma as a source of fibronectin. All of the 
fibronectin detectable by gel electrophoresis was removed 
from plasma by passage over either a gelatin or a P1 column 
(Fig.  9  A,  lane 2,  and 9  B,  lane  2),  whereas  the peptide 
P2 column did not remove any of the fibronectin (Fig. 9 B, 
lane  12).  The  bound  fibronectin  eluted  from the  gelatin- 
Sepharose column in 2-3 M urea (Fig. 9 A, lanes 5 and 6), 
while 3-4 M  urea was required to remove fibronectin from 
the PI-Sepharose column (Fig.  9  B,  lanes 6 and  7).  Apart 
from fibronectin, the preparation eluted from the P1 column 
contained some other plasma proteins, but the majority of 
these proteins eluted in the  1-2 M  urea fractions (Fig. 9 B, 
lanes 4 and 5),  indicating that they had a lower affinity for 
P1-Sepharose than did fibronectin. These experiments dem- 
onstrated that peptide P1 was able to bind directly and selec- 
tively to fibronectin. 
Discussion 
We have confirmed the previous finding by Chernousov et al. 
(1991) that the first type IU repeat of fibronectin is important 
for matrix assembly. In addition, we show that this site con- 
stitutes  a  fibronectin-fibronectin  binding  site  and  have 
reproduced some of the essential activities of this site with 
a  synthetic 31-amino acid peptide from that repeat. 
The role of the first type HI repeat in matrix assembly is 
likely to be different from the role of the amino-terminal 70- 
Figure 9. Affinity chromatography of  human plasma on peptide col- 
umns and gelatin-Sepharose. Human plasma was applied to either 
gelatin-Sepharose (A) or columns made ofpeptide P1 (B, lanes 1-11 ) 
or P2 (B, lanes 12 and 13) coupled to Sepharose. The unbound frac- 
tion of proteins was collected, and the columns were washed with 
PBS +  5 mM EDTA (PBS/EDTA). Proteins  remaining bound to 
the columns were eluted with stepwise urea gradients in the case 
of gelatin-Sepharose and P1-Sepharose, or 8 M urea in the case of 
P2-Sepharose.  A, lane  1 shows the starting  material,  and lane 2 
shows the unbound fraction from the gelatin column.  Lanes 3-11 
show the fractions eluted from gelatin-Sepharose by 0.5, 1, 2, 3, 4, 
5, 6, 7, and 8 M urea, in that order. B, lanes 1-11 are analogous to 
those of A except that they represent samples from the peptide P1 
column. B, lane 12 is the unbound fraction from the peptide P2 col- 
unto and lane 13 is the 8 M urea elution of  the P2 column and repre- 
sents all of the proteins eluted from the P2 column.  The proteins 
in the gels were stained with Coomassie blue. The lanes marked 
M depict molecular mass standards whose sizes are indicated to the 
left of each gel. The position of fibronectin is indicated to the right 
of each gel. 
and 29-kD regions. In contrast to the 70-kD fragment, which 
inhibits the binding of fibronectin to cell surfaces, our 14-kD 
fragment which represents the first type three repeat region 
only has a  small effect on the initial binding of fibronectin 
to cells, but has a pronounced effect on the subsequent incor- 
poration of fibronectin into the matrix. This indicates that 
the site contained in the  14-kD fragment functions during 
matrix assembly at a stage which is later than the initial bind- 
ing of fibronectin to cells.  Fibronectin binds to cell layers 
through its amino-terminal 70-kD region (McKeown-Longo 
and Mosher, 1985), which does not contain the 14-kD region 
(see Fig. 2).  Two proteins have been detected that are able 
to bind the 70-kD fragment (Limper et al.,  1991;  Blystone 
Morla and Ruoslahti Fibronectin Self-assembly  Site  427 and Kaplan, 1992); these may serve as the cell surface recep- 
tors for the binding of fibronectin to cell layers. In this report 
we show that the 14-kD fragment also binds to cell layers. 
The identity of the molecule on the cell surface that binds 
to the 14-kD region was not directly tested in our study, how- 
ever, since our results reveal a strong affinity in the  14-kD 
fragment for fibronectin, it is likely that the 14-kD fragment 
is binding to cell surface-bound fibronectin. 
Several lines of evidence suggest that the 14-kD fragment 
contains a site that allows fibronectin to bind to itself but that 
this site is partly cryptic in intact fibronectin. We find that 
while the binding of radiolabeled  14-kD fragment to cell 
layers is readily inhibited by excess unlabeled  14-kD frag- 
ment, intact fibronectin is a poor inhibitor of this interaction. 
Similarly,  the binding  of radiolabeled  14-kD  fragment to 
fibronectin coated onto plastic is also blocked by unlabeled 
14-kD fragment but not by unlabeled fibronectin. The reason 
that fibronectin does not compete effectively for the bind- 
ing may be that it also associates with cell surface-bound 
fibronectin (or fibronectin bound to a dish), and that the 14- 
kD fragment can then bind to the adsorbed fibronectin. The 
higher binding efficiency of the  14-kD-fibronectin interac- 
tion as compared to the fibronectin-fibronectin interaction 
may be due to the binding site in the 14-kD fragment being 
partially cryptic. However, since the  14-kD fragment was 
able to inhibit the self-association of intact fibronectin, the 
14-kD region is at least partially active in intact fibronectin 
molecules. The parallel between the two assays indicates that 
the mechanism of binding may be the same in both cases. It 
is  therefore likely that the  14-kD  fragment is  binding  to 
fibronectin on the surface of cells when it binds to cell layers. 
Our results indicate that while the role of the 14-kD region 
during matrix assembly is distinct from that of the 70- and 
29-kD regions, it may be more similar to that of the 56-kD 
region. The 14-kD region and the peptide P1  site are con- 
tained  in  the  56-kD  region,  and  a  40-kD  gelatin-binding 
fragment, which constitutes the majority of the 56-kD re- 
gion, is known not to inhibit matrix assembly (McDonald et 
al.,  1987; Quade and McDonald,  1988). Therefore, the 14- 
kD region would appear to be the active site in the 56-kD 
region. However, Chernousov et al. (1991) did not detect any 
binding of the 56-kD fragment to fibronectin, whereas we 
found that both the 14-kD fragment and peptide P1 did bind 
to it. On the other hand, a 60-kD gelatin and heparin-binding 
chymotryptic fragment of fibronectin which would appear to 
be essentially the same as the 56-kD fragment was found to 
contain a fibronectin-binding site (Ehrismann et al.,  1981, 
1982).  Since  the  high  affinity  of the  14-kD  region  for 
fibronectin is likely to be cryptic, this may explain the varia- 
tions in the fibronectin binding of the various larger frag- 
ments. 
By  expressing  recombinant  forms  of rat  fibronectin in 
mouse  cells,  Schwarzbauer  et  al.  (1987)  have  identified 
regions of fibronectin that are required for matrix assembly 
(Schwarzbauer  et  al.,  1987;  Schwarzbauer,  1991).  The 
smallest recombinant fibronectin that was efficiently incor- 
porated into the matrix contained the amino- and carboxy- 
terminal regions of the molecule with an internal deletion 
comprising the first seven type III repeats (Schwarzbauer, 
1991). This recombinant molecule did not contain the 14-kD 
region, seemingly indicating that this region may not be re- 
quired for fibronectin matrix assembly. However, although 
the  recombinant  fibronectins  were  incorporated  into  a 
deoxycholate-insoluble matrix,  they  may  not  have  been 
disulfide cross linked into high molecular weight multimers 
(Fig. 5 in Schwarzbauer,  1991),  as is always the case with 
wild  type fibronectin in  the  matrix  (Hynes and  Destree, 
1977; Keski-Oja et al.,  1977; Ali and Hynes, 1978). It re- 
mains to be seen whether the incorporation of the recom- 
binant fibronectins is identical to that of wild type fibronec- 
tin. In addition, it is known that exogenous and endogenous 
fibronectin molecules can be  incorporated into  the  same 
fibrils (Peters et al.,  1990). It is therefore possible that the 
incorporation of  the recombinant fibronectins into the matrix 
may  have  relied  partially  on  the  wild  type,  endogenous 
fibronectin that was being produced by the cells during the 
assay. 
The results presented in this study, as well as results ob- 
tained by other investigators (McDonald, 1988; Akiyama et 
al.,  1991;  Chernousov et al.,  1991;  Mosher et al.,  1991; 
Nagai et al., 1991; Schwarzbauer, 1991), are consistent with 
the following multi-step model for fibronectin matrix assem- 
bly. This model is similar to the models proposed by Mosher 
et  al.  (1991)  and  other  investigators  (McDonald,  1988; 
Hynes, 1990). The first step in the model is the capture of 
fibronectin dimers from the environment. This step is likely 
to involve the us/3~ integrin and the molecules which bind 
to  the  amino-terminal  70-kD  region,  since  antibodies  to 
a5/3~ and the 70-kD fragment of fibronectin both inhibit the 
binding of fibronectin to cells.  Since the  14-kD fragment 
only has a minor effect on the binding of fibronectin to cells, 
it probably does not inhibit matrix assembly at this step. The 
second step is translocation of the captured fibronectin to the 
growing end of a  fibronectin fiber.  This  step may not be 
necessary if a new fiber can be nucleated at the original loca- 
tion.  The third  step  is  fibronectin-fibronectin alignment. 
This  step  is  likely to  involve regions  of fibronectin self- 
association,  and we propose that this is probably the step 
which is inhibited by the 14-kD fragment. The fourth step 
is disulfide cross linking of the aligned molecules, resulting 
in covalent stabilization of the fibronectin fibril. 
There is evidence to suggest an inverse relationship be- 
tween the ability of a cell to migrate and the ability to assem- 
ble  a  fibronectin matrix.  For example,  CHO cells which 
overexpress a recombinant cts/3~ integrin produce more ma- 
trix than cells which do not overexpress the integrin (Gian- 
cotti and Ruoslahti, 1990). Migration studies with these cells 
indicate that the ceils which produce the most matrix migrate 
the least (Giancotti and Ruoslahti,  1990). The 14-kD frag- 
ment and peptide P1 may provide useful probes of the effects 
of matrix  production  on  cell  attachment  and  migration. 
While the P1 peptide clearly contains a fibronectin-binding 
site, we have not been able to achieve satisfactory inhibition 
of matrix formation in living cells by using the synthetic pep- 
tides (results not shown). The low activity of peptide P1 re- 
quires the use of high concentrations of the peptide for an 
effect on matrix formation and these effective concentrations 
are  too  close  to  the  concentrations  causing  nonspecific 
effects for the matrix inhibition to be convincing. While the 
14-kD fragment at this time remains the only fully effective 
probe  for  the  fibronectin-fibronectin  binding  site,  our 
identification of this site in the synthetic peptide should allow 
for the design of improved probes for matrix assembly. 
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